Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ctDNA Guided Palliative Systemic Therapy Compared to Standard Care in Metastatic Cancer - The Randomized ctDNA-RECIST Trial

NCT06562348 is registered in ClinicalTrials.gov with Karen-Lise Garm Spindler as lead sponsor.

NCT NCT06562348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06562348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ctDNA Guided Palliative Systemic Therapy Compared to Standard Care in Metastatic Cancer - The Randomized ctDNA-RECIST Trial
Lead sponsor
Karen-Lise Garm Spindler
Phase
Phase 2
Overall status
Recruiting
Start date
January 15, 2025
Completion date
September 1, 2030
Enrollment
167 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal neoplasm